Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 16/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 3/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765474 | 0.91 | F2 (0.38) | F2PRSS1PRSS2PRSS3ADORA3 | |
| SCHEMBL30765942 | 0.87 | NAMPT (0.42) | F2PRSS1PRSS2PRSS3ELANE | |
| SCHEMBL30765437 | 0.86 | HDAC6 (0.41) | F2PRSS1ELANE | |
| SCHEMBL30765711 | 0.86 | F2 (0.42) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL30765550 | 0.86 | F2 (0.38) | F2PRSS1ELANE | |
| SCHEMBL30765527 | 0.84 | NAMPT (0.44) | F2PRSS1PRSS2PRSS3ELANE | |
| SCHEMBL30765716 | 0.84 | F2 (0.37) | F2PRSS1PRSS2PRSS3ELANE | |
| SCHEMBL30766063 | 0.84 | F2 (0.40) | F2PRSS1PRSS2PRSS3ELANE | |
| SCHEMBL30765489 | 0.84 | F2 (0.39) | F2PRSS1PRSS2PRSS3ELANE | |
| SCHEMBL30766118 | 0.82 | ELANE (0.41) | F2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |